Safety and Effectiveness of Me-4FDG PETCT Scan for Early Detection of Lung Adenocarcinoma

What this Trial Is About

Researchers are evaluating a new type of positron emission tomography PET scan using a special tracer called Me-4FDG to detect lung cancer early. This phase III clinical trial focuses on lung adenocarcinoma and aims to assess both the safety and effectiveness of the Me-4FDG tracer in identifying cancer cells by tracking glucose uptake through the sodium-glucose transport protein SGLT2. Understanding this method may help improve early diagnosis of lung cancer. Participants receive an intravenous injection of the Me-4FDG tracer followed by a PETCT scan lasting about 15 minutes. The trial includes both patients with confirmed lung adenocarcinoma and those with lung nodules considered benign based on imaging guidelines. After the scan, patients are monitored for any adverse effects and followed up seven days later. During the study, researchers measure how sensitive and specific the Me-4FDG PET scans are in detecting lung cancer, comparing results with surgical or biopsy findings. They also examine how tracer uptake relates to tumor grade and expression of SGLT2 in tissue samples. Safety is monitored from the time of tracer injection to one week afterward. The total participation involves the initial scan and a follow-up visit about one week later.

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer